GGrantIndex
Sort

17,054 grants matching genome editing

Project 3 Topological mapping of chromatin architectures for hormone-independent gene transcription

$357,000
Victor Jin · University Of Texas Hlth Science Center · U54 · FY2020 · CA

Forward and Reverse Genetic Studies of AIS and Spine Development in Zebrafish

$356,970
Lilianna Solnica-Krezel · Ut Southwestern Medical Center · P01 · FY2022 · HD

Tissue Damage-Driven Squamous Cell Carcinoma

$356,850
Andrew South · Thomas Jefferson University · R01 · FY2021 · CA

Molecular Dissection of an Arntl2 induced pro-metastatic secretome

$356,780
Monte Meier Winslow · Stanford University · R01 · FY2019 · CA

Somatic Mutation in the Etiology of Multiple Sclerosis

$356,730
Richard H Scheuermann · J. Craig Venter Institute, Inc. · R21 · FY2016 · AI

Molecular mechanisms underlying cortical interneuron synaptic specificity

$356,640
Hiroki Taniguchi · Ohio State University · R01 · FY2022 · NS

Therapeutic pathway reprogramming for metabolic liver disease

$356,625
Karl-Dimiter Bissig · Baylor College Of Medicine · R01 · FY2018 · DK

The role of Spry2 in beta cell function and the unfolded protein response

$356,625
Gregory Michael Ku · University Of California, San Francisco · R01 · FY2018 · DK

The role of Spry2 in beta cell function and the unfolded protein response

$356,625
Gregory Michael Ku · University Of California, San Francisco · R01 · FY2020 · DK

The role of Spry2 in beta cell function and the unfolded protein response

$356,625
Gregory Michael Ku · University Of California, San Francisco · R01 · FY2016 · DK

The role of Spry2 in beta cell function and the unfolded protein response

$356,625
Gregory Michael Ku · University Of California, San Francisco · R01 · FY2017 · DK

The role of Spry2 in beta cell function and the unfolded protein response

$356,625
Gregory Michael Ku · University Of California, San Francisco · R01 · FY2019 · DK

Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS

$356,539
Thomas Gaj · University Of Illinois At Urbana-Champaign · R01 · FY2024 · NS

Functional role of dual neurotransmission in aggression

$356,521
Ronald Steven Stowers · Montana State University - Bozeman · R01 · FY2023 · GM

Testing the Therapeutic Potential of iPS Cells for Inherited Skin Diseases

$356,513
Dennis Roop · University Of Colorado Denver · R01 · FY2012 · AR

Biology and Biotechnology of Cell and Gene Therapy

$356,503
David V Schaffer · University Of California Berkeley · T32 · FY2021 · GM

Molecular Mechanisms of Axenfeld-Rieger Syndrome

$356,250
Elena V Semina · Medical College Of Wisconsin · R01 · FY2013 · EY

Development and Application of New Genome Editing Tools for the Functional Investigation of Genetic Variants of Uncertain Significance

$356,242
Alexis C. Komor · University Of California, San Diego · R35 · FY2023 · GM

Development and Application of New Genome Editing Tools for the Functional Investigation of Genetic Variants of Uncertain Significance

$356,242
Alexis C. Komor · University Of California, San Diego · R35 · FY2024 · GM

Development and Application of New Genome Editing Tools for the Functional Investigation of Genetic Variants of Uncertain Significance

$356,242
Alexis C. Komor · University Of California, San Diego · R35 · FY2022 · GM

Hepatic Aryl Hydrocarbon Receptor Regulation of Obesity: Mechanisms of Action

$356,219
Cornelis Johan Elferink · University Of Texas Med Br Galveston · R01 · FY2023 · ES

Hepatic Aryl Hydrocarbon Receptor Regulation of Obesity: Mechanisms of Action

$356,219
Casey W Wright · University Of Texas Med Br Galveston · R01 · FY2024 · ES

Hepatic Aryl Hydrocarbon Receptor Regulation of Obesity: Mechanisms of Action

$356,219
Cornelis Johan Elferink · University Of Texas Med Br Galveston · R01 · FY2022 · ES

Hepatic Aryl Hydrocarbon Receptor Regulation of Obesity: Mechanisms of Action

$356,219
Casey W Wright · University Of Texas Med Br Galveston · R01 · FY2025 · ES

Project 3: Targeted therapy for splicing factor mutant myeloid malignancies

$356,195
Matthew J Walter · Washington University · P50 · FY2025 · CA